3X Genetics Raises $3.16 Million Seed Round to Advance AI-Driven Diagnostics for Rare Genetic Disorders
3X Genetics, a Massachusetts-based biotechnology company developing precision diagnostics for repeat expansion and genetic disorders, has raised $3.16 million in seed funding as it works to expand its AI-driven genetic testing platform and advance clinical adoption of its targeted sequencing technology.
The company specializes in molecular diagnostic solutions for repeat expansion disorders (REDs), a class of genetic diseases that are often difficult to detect using conventional sequencing methods. These conditions include diseases such as myotonic dystrophy and other inherited neurological and neuromuscular disorders where traditional short-read sequencing techniques frequently fail to identify pathogenic variations. 3X Genetics uses a proprietary targeted, unamplified sequencing approach combined with computational analysis to improve detection accuracy in these complex genomic regions.
Founded in 2021 by engineer and entrepreneur Kevin Donahue, the company originated from efforts to solve long-standing diagnostic challenges in genetic medicine, particularly in cases where patients experience years of inconclusive testing. The company is headquartered in Worcester, Massachusetts, with laboratory operations in Manchester, New Hampshire, where it conducts clinical-grade testing through a CLIA-certified facility.
The $3.16 million seed round brings the company closer to a targeted $4 million total raise, according to publicly available disclosures. The financing reflects continued investor interest in precision diagnostics and genomic technologies aimed at improving rare disease detection. While the lead investor was not publicly disclosed, the round included participation from Alumni Ventures, Morningside Group, Wire Group (Massachusetts), and Massachusetts Biomedical Initiatives, a nonprofit life sciences incubator and accelerator that supports early-stage biotech companies in the region.
Alumni Ventures has been active in backing early-stage life sciences and deep-tech startups across the United States, focusing on scalable innovations in healthcare and diagnostics. Morningside Group, a global investment firm known for its long-term approach to life sciences and biotechnology investing, also participated in the round, signaling institutional confidence in 3X Genetics’ approach to addressing gaps in genetic testing infrastructure.
Wire Group, a Massachusetts-based investor group, and Massachusetts Biomedical Initiatives, which provides both funding and incubation support to early-stage biotech companies in the Worcester region, further reinforced the company’s local ecosystem backing. Their involvement highlights the role of regional innovation clusters in supporting emerging diagnostics companies during early commercialization phases.
The funding is expected to support expansion of 3X Genetics’ testing platform, including scaling its laboratory operations, advancing assay development, and expanding collaborations with biopharmaceutical companies, academic institutions, and clinical research organizations. The company also works closely with partners in drug development, using its diagnostic platform to support therapeutic research in genetically defined patient populations.
3X Genetics’ technology platform integrates AI-assisted assay design with advanced molecular biology techniques to analyze previously difficult genomic regions. By focusing on repeat expansion disorders, the company targets a diagnostic category that has historically been under-served due to technical limitations in standard genetic testing workflows. Its approach aims to reduce diagnostic timelines and improve accuracy for patients who often undergo prolonged diagnostic journeys.
As genomic medicine continues to evolve, companies like 3X Genetics are increasingly positioned at the intersection of diagnostics and therapeutic development. The ability to accurately identify genetic variants associated with rare diseases is becoming essential not only for clinical diagnosis but also for enabling precision medicine and targeted drug development strategies.
With new seed funding secured, 3X Genetics is preparing to scale its platform, expand clinical adoption, and deepen its partnerships across the biotechnology and healthcare ecosystem, strengthening its position in the rapidly growing field of precision genetic diagnostics.
